President Trump’s expected move to ease federal marijuana restrictions is shaking up both Wall Street and Main Street, raising fresh questions about drug policy, public safety, and the proper role of government.
Story Highlights
- Trump is expected to sign an executive order directing agencies to reclassify marijuana from Schedule I to Schedule III.
- Pot stocks exploded higher on the news, with some companies surging more than 50% in a single day.
- Rescheduling could ease taxes, open bank access, and accelerate national normalization of marijuana.
- Conservatives now face a key debate: limited government and federalism versus fears of cultural and public health fallout.
Trump’s Expected Marijuana Order and What It Actually Does
President Trump is expected as soon as Monday to sign an executive order instructing federal agencies to move marijuana from the most restrictive Schedule I classification, where it currently sits alongside heroin, into Schedule III, which includes drugs like certain steroids and Tylenol with codeine.
The move would not fully legalize cannabis nationwide, but it would direct the bureaucracy to treat marijuana as a lower-risk, medically recognized substance and trigger a lengthy regulatory process to formalize that shift.
The proposed reclassification would immediately change how federal law views both medical and recreational marijuana businesses that have been operating in a gray area for years.
Schedule I status currently blocks banks from comfortably serving the industry, complicates research, and subjects companies to punishing tax rules that prevent normal business deductions.
Moving to Schedule III would loosen those constraints, potentially allowing mainstream banks, investors, and insurers to enter a market that has largely been pushed to the financial sidelines.
Trump expected to sign executive order to reclassify marijuana as soon as Monday, source tells CNBC; pot stocks surge
/position+ $MSOS 🇺🇸🌿https://t.co/Bra5IC45rv pic.twitter.com/72wIorjOcd
— Todd Harrison (@todd_harrison) December 12, 2025
Why Cannabis Stocks Just Went Through the Roof
Financial markets reacted instantly and aggressively to the expectation of Trump’s executive order, with cannabis stocks erupting higher on Friday’s trading session.
Producers Tilray Brands and Canopy Growth each soared more than forty percent, while cannabis-focused real estate operator Innovative Industrial Properties climbed nearly nine percent.
A broader marijuana exchange-traded fund posted its best day on record, surging more than fifty percent, as traders bet that lower regulation, friendlier tax treatment, and new capital inflows could breathe life into a sector that has struggled for years.
Wall Street analysts framed the anticipated move as the long-awaited catalyst the industry had been waiting for, rather than a surprise ideological pivot.
One investment banker wrote to clients that rescheduling marijuana was always a question of when rather than if, describing the shift as broadly positive for cannabis businesses and the financial institutions that have been wary of touching them.
Analysts now expect that, once Trump signs the order, the Drug Enforcement Administration will advance a formal rule reclassifying marijuana by next summer, barring court challenges or bureaucratic delays.
Conservative Tension: Limited Government vs. Moral and Public Health Concerns
For conservative readers, this development hits several sensitive fault lines at once: personal liberty, public safety, cultural decline, and the proper scope of Washington’s power.
Many limited-government conservatives have long argued that treating marijuana like heroin never made sense, that states should decide their own policies, and that federal overreach created black markets and fueled crime.
Rescheduling aligns with that instinct by pulling Washington back from its harshest posture and letting markets and states play a larger role, at least on taxation and banking access.
At the same time, parents, pastors, and law-and-order advocates rightly worry about the broader normalization of drug use and its impact on families, schools, and communities already strained by addiction and broken homes.
Reclassification does not legalize recreational use nationwide, but it will likely be framed by activists as a scientific endorsement of marijuana’s safety and a step toward full federal legalization.
That raises concerns about more impaired driving, youth access through looser cultural norms, and another industry spending heavily to market a mind-altering product in already overstressed neighborhoods.
Industry Optimism, Legal Battles, and the Road Ahead
Leaders in the cannabis industry view Trump’s expected order as the start of what they call a “new era” in federal drug policy, and their language underscores how far they hope this goes.
Executives are openly optimistic that reclassification will accelerate the normalization of marijuana under national law, unlock serious institutional investment, and pressure Congress to craft a broader regulatory framework touching safety, access, and criminal justice.
Industry-aligned attorneys, while calling this move only a partial victory, describe it as a powerful lever to demand additional reforms from lawmakers.
Legal and constitutional questions will not disappear with the stroke of a pen. Analysts are closely watching whether the Supreme Court agrees to hear cases that challenge the conflict between state-level legalization and ongoing federal prohibition.
A favorable ruling for the industry could shorten regulatory timelines and weaken Washington’s remaining leverage, while an unfavorable one might slow or complicate the rescheduling process.
For conservatives, the next chapter will be deciding how to balance federalism, public order, and personal responsibility in a rapidly shifting landscape.
